Processa Pharmaceuticals, Inc.: 10-Q filed 2017-11-20
What Processa Pharmaceuticals, Inc. reported in its quarterly report filed 2017-11-20 (fiscal Q3 2017): 27 published measures, 62 facts as tagged in accession 0001393905-17-000369.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2017-11-20
- Fiscal period
- fiscal Q3 2017
- Accession
- 0001393905-17-000369 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Processa Pharmaceuticals, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 80,262 | USD | |
| At 2016-12-31 | 3,237 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 115,314 | USD | |
| At 2016-12-31 | 2,354,393 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | -35,052 | USD | |
| At 2016-12-31 | -2,351,156 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 80,262 | USD | |
| At 2016-12-31 | 3,237 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-09-30 | -204,413 | USD | 92 |
| 2017-01-01 to 2017-09-30 | -322,891 | USD | 273 |
| 2016-07-01 to 2016-09-30 | -68,333 | USD | 92 |
| 2016-01-01 to 2016-09-30 | -245,158 | USD | 274 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-09-30 | -249,975 | USD | 273 |
| 2016-01-01 to 2016-09-30 | -36,206 | USD | 274 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-09-30 | 5,000 | USD | 274 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-09-30 | 327,000 | USD | 273 |
| 2016-01-01 to 2016-09-30 | 15,000 | USD | 274 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-09-30 | 17,000 | USD | 274 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | -17,036,341 | USD | |
| At 2016-12-31 | -16,681,333 | USD |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-09-30 | -1,931 | USD | 92 |
| 2017-01-01 to 2017-09-30 | -1,931 | USD | 273 |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-09-30 | 6,691 | USD | 274 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 80,262 | USD | |
| At 2016-12-31 | 3,237 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-09-30 | 44,158 | USD | 92 |
| 2017-01-01 to 2017-09-30 | 169,513 | USD | 273 |
| 2016-07-01 to 2016-09-30 | 63,322 | USD | 92 |
| 2016-01-01 to 2016-09-30 | 182,062 | USD | 274 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 115,314 | USD | |
| At 2016-12-31 | 2,354,393 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 95,568 | USD | |
| At 2016-12-31 | 166,165 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-09-30 | 163,771 | USD | 92 |
| 2017-01-01 to 2017-09-30 | 187,806 | USD | 273 |
| 2016-07-01 to 2016-09-30 | 4,969 | USD | 92 |
| 2016-01-01 to 2016-09-30 | 94,465 | USD | 274 |
Gross profit
Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-09-30 | 5,000 | USD | 274 |
Selling, general and administrative expense
Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-09-30 | 163,771 | USD | 92 |
| 2017-01-01 to 2017-09-30 | 187,640 | USD | 273 |
| 2016-07-01 to 2016-09-30 | 4,395 | USD | 92 |
| 2016-01-01 to 2016-09-30 | 88,194 | USD | 274 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-09-30 | 166 | USD | 273 |
| 2016-07-01 to 2016-09-30 | 574 | USD | 92 |
| 2016-01-01 to 2016-09-30 | 6,271 | USD | 274 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 24,690,790 | shares | |
| At 2016-12-31 | 11,017,388 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 16,998,820 | USD | |
| At 2016-12-31 | 14,329,057 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 19,746 | USD | |
| At 2016-12-31 | 134,513 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-09-30 | -202,482 | USD | 92 |
| 2017-01-01 to 2017-09-30 | -320,960 | USD | 273 |
| 2016-07-01 to 2016-09-30 | -68,291 | USD | 92 |
| 2016-01-01 to 2016-09-30 | -246,372 | USD | 274 |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-09-30 | -204,413 | USD | 92 |
| 2017-01-01 to 2017-09-30 | -322,891 | USD | 273 |
| 2016-07-01 to 2016-09-30 | -79,157 | USD | 92 |
| 2016-01-01 to 2016-09-30 | -277,392 | USD | 274 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-09-30 | 159 | USD | 274 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-09-30 | -34,238 | USD | 273 |
| 2016-01-01 to 2016-09-30 | 14,575 | USD | 274 |
Inspect the source
- Entity
- Processa Pharmaceuticals, Inc. / CIK 0001533743
- Captured
- 2026-09-20T09:16:31.348Z
- SEC response SHA-256
5f3216d9024f2a7fc94b315f5bf243c7efb048273a6be394a2f74186d7af2a31
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001533743.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))